Armistice Capital, LLC's Form 4 filing
Avalo Therapeutics, Inc. (AVTX) · filed Jun 28, 2023
- Accession no.
- 0000899243-23-016659
- Filed
- Jun 28, 2023, 6:12 PM ET
- Trade date
- Jun 26-27, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $2.17M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Armistice Capital, LLCCIK 0001601086 | 10% Owner |
| Armistice Capital Master Fund Ltd.CIK 0001633584 | 10% Owner |
| Boyd StevenCIK 0001706140 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 26, 2023 | Common Stock | SSaleDisposed | −2,746,138 | $0.6125 | −$1,682,009.53 | 1,668,862 | Indirect | |
| Jun 27, 2023 | Common Stock | SSaleDisposed | −937,404 | $0.5194 | −$486,887.64 | 731,458 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.